CEL-SCI CORP
CVMNYSE AMERICANTrading Snapshot
- Day Range
- $1.73 – $1.74
- 52-Week Range
- $0.89 – $10.83
- Volume
- $2.61B
- Avg Volume
- $2.88B
- Shares Outstanding
- 17.5M
- Next Earnings
- Nov 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $568,706
- Last Q Revenue
- $155,245
- P/E Ratio
- —
- P/S Ratio
- 52.6x
- EPS (TTM)
- $-2.68
- Dividend Yield
- —
- Dilution (1yr)
- +268.1%
Why Investors Own CVM
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CEL-SCI CORP
CVM
StockOtter · stockotter.spaceAbout CEL-SCI CORP
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CEL-SCI CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CVM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CEL-SCI CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.